CYCC vs. DRMA, CNSP, CYTO, NTBL, SLRX, CWBR, ONCO, RNAZ, AGRX, and CMND
Should you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Dermata Therapeutics (DRMA), CNS Pharmaceuticals (CNSP), Altamira Therapeutics (CYTO), Notable Labs (NTBL), Salarius Pharmaceuticals (SLRX), CohBar (CWBR), Onconetix (ONCO), TransCode Therapeutics (RNAZ), Agile Therapeutics (AGRX), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical preparations" industry.
Dermata Therapeutics (NASDAQ:DRMA) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Cyclacel Pharmaceuticals has a consensus price target of $21.00, indicating a potential upside of 1,212.50%. Given Dermata Therapeutics' higher possible upside, analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Dermata Therapeutics.
Cyclacel Pharmaceuticals' return on equity of -107.95% beat Dermata Therapeutics' return on equity.
Dermata Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Dermata Therapeutics has higher earnings, but lower revenue than Cyclacel Pharmaceuticals. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cyclacel Pharmaceuticals had 3 more articles in the media than Dermata Therapeutics. MarketBeat recorded 4 mentions for Cyclacel Pharmaceuticals and 1 mentions for Dermata Therapeutics. Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.
Cyclacel Pharmaceuticals received 182 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 49.34% of users gave Cyclacel Pharmaceuticals an outperform vote while only 44.44% of users gave Dermata Therapeutics an outperform vote.
8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 9.4% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Cyclacel Pharmaceuticals beats Dermata Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Cyclacel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclacel Pharmaceuticals Competitors List
Related Companies and Tools
